PyL PSMA | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

3,307 results for “PyL PSMA”

Trials

View all 1496 →

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

184 participants · First posted Jan 7, 2021

Active, not recruiting

Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.

50 participants · First posted Dec 7, 2020

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

45 participants · First posted Jul 8, 2025

Drugs

View all 1445 →

PSMA-ADC-1301

64Cu RMX-PSMA

PSMA-GCK01

Organizations

Puma Biotechnology

United States

ANIRBAN PAL

India

PDL BIOPHARMA, INC.

United States

News

View all 360 →

18F-Flotufolastat Shows High Detection Rate in Prostate Cancer Recurrence with Low PSA

Advancements in PSMA-Targeted Radionuclide Therapy for Metastatic Prostate Cancer

PSMA PET-CT Improves Prostate Cancer Metastasis Detection

Page 1 of 331